DermaSensor’s core product is a wireless, handheld optical-spectroscopy device that assesses skin lesions at a cellular level, delivering automated skin-cancer detection for use in primary care settings. Cleared by the FDA via the De Novo pathway in early 2024, it is the only automated skin-cancer detection device available to U.S. primary-care physicians. Since its mid-2024 commercial launch, clinicians have scanned more than 20,000 lesions with the device, and usage is growing at an average quarterly rate of 117%. Published studies report sensitivity between 96-100% and specificity up to 77% for pigmented lesions, performance that has been highlighted in Nature and honored by TIME’s Best Inventions of 2024. The company’s AI training dataset has already grown several-fold beyond the original 2,000 lesions, and management cites approximately 2,000 suspicious cancers detected for referral to dermatology. Beyond the cleared algorithm, DermaSensor has three active pipeline programs that will run on the same hardware. To date the company has attracted $43 million in total investment, supporting both commercial expansion and additional clinical evidence generation.

Total raised

$38M

Funding rounds

3

Latest round

Series B

Latest activity

Oct 2025